

IN THE CLAIMS

Add claims 39-53, which follow:

- 31
- Claim 39: A method for determining if any analyte binds to an activin receptor like kinase (ALK), comprising contacting a sample containing said analyte to an ALK and substance which specifically binds to said ALK, and determining binding of said analyte to said ALK in the presence of said antibody to determine an ALK binding analyte.
- Claim 40: The method of claim 39, further comprising determining if said analyte antagonizes said ALK.
- Claim 41: The method of claim 39, wherein said ALK is in soluble form.
- Claim 42: The method of claim 39, wherein said ALK is expressed by a transfected cell.
- Claim 43: The method of claim 42, wherein said transfected cell is a eukaryotic cell.
- Claim 44: The method of claim 39, wherein said substance is a member of the TGF- β superfamily.
- Claim 45: The method of claim 44, wherein said member of TGF- β superfamily is TGF- β activin, inhibin, a bone morphogenic protein or a Müllerian inhibiting substance.
- Claim 46: The method of claim 39, wherein said substance is an antibody.
- Claim 47: The method of claim 46, wherein said antibody is a monoclonal antibody.
- Claim 48: The method of claim 47, wherein said antibody binds to an extracellular domain of said ALK.
- Claim 49: The method of claim 39, comprising determining if said analyte binds via an enzyme linked immunoassay.
- Claim 50: The method of claim 39, wherein said sample is a tissue extract.
- Claim 51: The method of claim 39, wherein said sample is conditioned media.
- Claim 52: The method of claim 39, comprising determining said binding via determination of cross linked immunocomplexes.